Clinical trials: Thiotepa
Leukemia, Lymphocytic, Acute, Leukemia, Myelocytic, Acute
Randomized Double Cord Blood Transplant Study
The goal of this clinical research study is to learn if combining cord blood units to make the cells "take" faster in recipients will help to improve the results of cord blood transplants.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Myelocytic, Acute, Leukemia, Myeloid, Chronic, Lymphoma, Non-Hodgkin
- Trial name
- NCT00067002
- Testing
- Expanded allogeneic cord blood (CB), One Unmanipulated and One Expanded Cord Blood Unit, Rituxan
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- M.D. Anderson Cancer Center
Stem Cell Transplantation, Leukemia
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn if thiotepa, busulfan, and clofarabine, when given before an…
- Conditions
- Stem Cell Transplantation, Leukemia, Lymphoma
- Trial name
- NCT00857389
- Testing
- Thiotepa, Clofarabine, Busulfan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
This pilot phase II trial studies how well a new reduced intensity conditioning regimen that includes haploidentical donor NK cells followed by the infusion of selectively T-cell depleted progenitor cell grafts work in treating…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02259348
- Testing
- Cyclophosphamide, Fludarabine, G-CSF
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
Brain Tumors
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
The purpose of this study is to: Find out how safe and effective (by monitoring the good and/or bad effects) treatment with high dose temozolomide, thiotepa and carboplatin with stem cell rescue followed by 13-cis-retinoic acid…
- Trial name
- NCT00528437
- Testing
- temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
- Where
- 17 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- NYU Langone Health
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
This phase II trial investigates side effects and how well donor stem cell transplant after chemotherapy works in treating pediatric and adolescent-young adults with high-risk solid tumor that has come back (recurrent) or does…
- Conditions
- Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor
- Trial name
- NCT04530487
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
The purpose of this study is to find out the effects of using a system called CliniMACS to remove Tcells from blood stem cells. Removing T-cells may help stop a side effect called Graft-Versus-Host Disease (GVHD).
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT01119066
- Testing
- total body irradiation, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 422 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo expanded cord blood progenitor cells (dilanubicel) works in treating patients with blood cancer.
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT03399773
- Testing
- Dilanubicel, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Fred Hutchinson Cancer Center
Sarcoma
Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
RATIONALE: Giving chemotherapy drugs, such as busulfan, melphalan, and thiotepa, before a donor stem cell transplant helps stop the growth of tumor cells and prepares the patient's bone marrow for the stem cells.
- Trial name
- NCT00357396
- Testing
- graft versus host disease prophylaxis/therapy, busulfan, melphalan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anemia, Aplastic, Amegakaryocytic Thrombocytopenia
Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias
Due to an overall and disease free survival of 85% to 100%, allogeneic blood or bone marrow stem cell transplantation using an HLA matched sibling donor is the therapy of choice for patients with severe aplastic anemia (SAA).
- Conditions
- Anemia, Aplastic, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Kostmann Syndrome
- Trial name
- NCT00244010
- Testing
- Allogeneic stem cell transplant
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- St. Jude Children's Research Hospital
Non-Malignant Hematologic Disorders
TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors
The purpose of this study is to find out if removing a specific type of white blood cell (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve results of blood stem cell transplant for the…
- Trial name
- NCT03615144
- Testing
- Melphalan, Thiotepa, Clofarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
B-cell Lymphomas
High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement
This prospective trial will assess the activity and feasibility of a new high-dose methotrexate-based high-dose sequential chemotherapy combination in patients with B-cell lymphomas and CNS involvement at diagnosis or relapse.
- Trial name
- SCNSL1 (NCT00801216)
- Testing
- High-dose sequential chemotherapy and autologous transplant
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Andrés José Maria Ferreri
Leukemia, Lymphoma
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
Donor: This clinical study will evaluate the feasibility of a purified CD34 peripheral blood progenitor cell (PBPC) transplants in patients with hematological malignancies.
- Trial name
- NCT00038857
- Testing
- Megadose of CD34 Selected Progenitor Cells, Melphalan, Thiotepa
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
This randomized phase II trial studies how well donor umbilical cord blood transplant with or without ex-vivo expanded cord blood progenitor cells works in treating patients with acute myeloid leukemia, acute lymphoblastic…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Myelogenous Leukemia
- Trial name
- NCT01690520
- Testing
- Cyclophosphamide, Cyclosporine, Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
- Where
- 8 sites in United States
- Volunteers
- 163 people
- Sponsor
- Nohla Therapeutics, Inc.
Wilms Tumor, Fibrosarcoma
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.
- Conditions
- Wilms Tumor, Fibrosarcoma, Carcinoma, Round Cell, Nasopharyngeal Cancer
- Trial name
- NCT00141765
- Testing
- Myeloablative Chemotherapy, Stem Cell Rescue
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Central Nervous System Lymphoma
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
This is a multicenter open label randomized phase II trial. Enrolled Primary Central Nervous System Lymphoma (PCNSL) patients will be stratified according to the IELSG score and randomized to receive one of the follows as primary…
- Trial name
- NCT01011920
- Testing
- Methotrexate, Ara-C, Rituximab
- Where
- 54 sites in Denmark, Germany and 3 more
- Volunteers
- 227 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Sickle Cell Disease
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD).
- Trial name
- NCT03263559
- Testing
- Haploidentical Bone Marrow Transplantation, Hydroxyurea, Rabbit-ATG
- Where
- 32 sites in United States
- Volunteers
- 95 people
- Sponsor
- Medical College of Wisconsin
Hematologic Malignancy, Myeloid Malignancy
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
The participants are being asked to take part in this clinical trial because the participant have a lymphoid or myeloid based cancer diagnosis that requires a bone marrow transplant.
- Trial name
- NCT05579769
- Testing
- Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- St. Jude Children's Research Hospital
CNS Lymphoma, CNS Brain Cancer
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma
The purpose of this study is to determine the safety of this new treatment offered in this study. PCNSL can be cured in less than half of patients with standard treatment, a combination of chemotherapy and brain radiation.
- Conditions
- CNS Lymphoma, CNS Brain Cancer, Non-Hodgkin's Lymphoma
- Trial name
- PCNSL (NCT00596154)
- Testing
- Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
This phase II trial studies the side effects of a cord blood transplant using dilanubicel and to see how well it works in treating patients with human immunodeficiency virus (HIV) positive hematologic (blood) cancers.
- Conditions
- Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT04083170
- Testing
- Fludarabine, Cyclophosphamide, Thiotepa
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
The purpose of this study is to compare safety and efficacy of reduced-intensity conditioning and myeloablative conditioning regimens prior to HSCT in high-risk AML/MDS pediatric and young adult patients.
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Hematopoietic Stem Cell Transplant (HSCT)
- Trial name
- NCT02626715
- Testing
- Reduced-Intensity Conditioning Regimen, Myeloablative Conditioning Regimen
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Randy Windreich